Complete Omics Clinical Proteomics

Revolutionize your research with deeper assays

Unmatched sensitivity and specificity of proteomics assays for confident results. Interested in Complete Omics technologies?
Get in touch
 

For Clinicians and Researchers

Complete Omics offers the most sensitive and specific proteomics assays available, so scientists can have the deepest and most accurate proteomics results for your samples and clinicians can have the best information to make treatment management decisions that lead to favorable patient outcomes. Our unmatched proteomics assays deliver the most demanded information when answering clinical and basic research questions: 

01
What proteins are in my samples?
02
What changes between my samples?
03
Are the findings reproducible?

by the numbers

Why choose Complete Omics?

When choosing the best service provider for your proteomics research needs, solid number of high-impact publications and patents are what you may want to focus on. Here is our specifications:

0+
Total Number of
Publications
20
Cell/Nature/Science
Papers
0 X
Total Number of
Patents

*For a selected list of our publications, please visit our company Publication page.

 

Ultra-sensitive

Valid-NEO® assays

Complete Omics Valid-NEO® is a multi-omics personalized cancer therapeutic target identification system. Valid-NEO begins with tumor whole-exome sequencing (WES) to identify patient-specific somatic mutations. A personalized Valid-NEO test is then developed to detect neoantigens encoded by these patient specific mutations.

 

Click to enlarge

Sensitive and Specific

Complete360® assays

Complete360® platform is purpose-built for ultra-sensitive protein biomarker detection in body fluid samples, such as plasma, and can be used to develop novel disease biomarkers, to detect early onset of human diseases, to monitor treatment response, and for recurrence surveillance.

 

Click to enlarge

Complete and High-impact

CompleteCohort® Services

CompleteCohort® is the most comprehensive clinical proteomics assays aiming for evaluating mult-omics information for a large cohort of samples. Powered by the same standards, softwares and reference samples used in world-renowed CPTAC (Clinical Proteomic Tumor Analysis Consortium) projects, CompleteCohort® is rooted in demonstrated academic success.

 

Click to enlarge

*For a list of CPTAC projects our co-founder has lead or participated in, please visit our Publication page.

HS-grid-items (3)

 

What Makes Us Different?

Complete Omics pipelines deliver unmatched discoveries, with successful publication of over 60 top profile papers including # on CELL, # on Nature, and # on Science journals, which translates to your research successs with fewer headache on how to publish high.

HS-grid-items (1)

 

Higher profile publication

With a record of >60x top profile publications, your studies will be designed towards top profile journals since day 1, dramatically improving your chance of paper publication.

 

Easier clinical insight evaluation

Higher quality data means molecular biology of diseases can be studied at deeper levels with greater insight into the particular question you are trying to answer compared to other methods.

 

High-confidence in clinical decisions

Complete Omics has been working with the world's best liquid biopsy team ever since it was founded. With alumni companies like Thrive Earlier Detection (acquired by Exact Science), PGDx (acquired by LabCorp), etc, we have a deep understanding about clinical needs...

 
 
 
 

 

Higher profile publication

With a record of >60x top profile publications, your studies will be designed towards top profile journals since day 1, dramatically improving your chance of paper publication.

 

Click to enlarge

 

Easier clinical insight evaluation

Higher quality data means molecular biology of diseases can be studied at deeper levels with greater insight into the particular question you are trying to answer compared to other methods.

 

Click to enlarge

 

High-confidence in clinical decisions

Complete Omics has been working with the world's best liquid biopsy team ever since it was founded. With alumni companies like Thrive Earlier Detection (acquired by Exact Science), PGDx (acquired by LabCorp), etc, we have a deep understanding about clinical needs...

 

Click to enlarge

 
 
floating border 1

News & Events

The Latest

Find out what's happening at Complete Omics and stay up-to-date with proteomics and molecular diagnostics industry news.

Complete Omics closed a new financing round invested by Qiming Venture Partners!

 

BALTIMORE, MD – November 28, 2023 --- In a significant move for the biotech industry, Complete Omics Inc., has announced the successful closure of its Series A financing round, with a notable investment from Qiming Venture Partners. This strategic partnership marks a pivotal moment for Complete Omics, enabling the company to accelerate its research and development efforts and expand its innovative diagnostics solutions globally.

 

Complete Omics announced the establishment of a chinese branch

 

The administration team and shareholders of Complete Omics are pleased to announce the establishment of a new branch in China, named KangPuBoAo (HangZhou) Biotechnology Inc. (“康普博奥（杭州）生物科技有限公司” in Chinese). This expansion positions Complete Omics as one of the select molecular diagnostic service companies with operations extending beyond national borders.

 
 
 
More news